ArriVent BioPharma, Inc. (AVBP)
$16.09-2.25%Close
SELLCRISIS · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $749M
- Beta
- 1.35
- P/E (TTM)
- -4.37
- Short % float
- 28.38%
- Days to cover
- 11.3
- SI change
- -3.6%
- 1W
- +6.63%
- 1M
- -43.68%
- vs SPY 1W
- +6.77%
- vs SPY 1M
- -46.19%
Industry peers
FMP comparable companies · ranked by market cap
- EXELBUYExelixis, Inc.$14.8BBULLQ 10$59.02-0.52%
- ERASSELLErasca, Inc.$5.4BRECOVERYQ 4$15.46-4.40%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 25$36.06-4.99%
- ZLABSELLZai Lab Limited$2.8BCRISISQ 8$24.81-6.06%
- HCMSELLHUTCHMED (China) Limited$2.4BRECOVERYQ 5$13.67-1.32%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$4.95-3.67%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$12.03-4.23%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 4$19.97-5.31%
- PBYIBUYPuma Biotechnology, Inc.$507MBULLQ 13$9.97-1.65%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on AVBP?
- LOPJLB’s latest quantitative signal on ArriVent BioPharma, Inc. (AVBP) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AVBP in?
- ArriVent BioPharma, Inc. (AVBP) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ArriVent BioPharma, Inc. (AVBP) do?
- ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The companyâs lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mu…